2 assets in Autoimmune Lymphoproliferative Syndrome Due To CTLA4 Haploinsufficiency

Therapeutic assets addressing Autoimmune Lymphoproliferative Syndrome Due To CTLA4 Haploinsufficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
TIL Autoimmune Lymphoproliferative Syndrome Due To CTLA4 Haploinsufficiency	Second Affiliated Hospital of Guangzhou Medical University	P1	CC (43)
imm27m Autoimmune Lymphoproliferative Syndrome Due To CTLA4 Haploinsufficiency	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1	NR ()